# CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

> **NCT04156178** · EARLY_PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- B Cell Lymphoma
- B Cell Leukemia

## Interventions

- **BIOLOGICAL:** CD20-CD19 cCAR T cells

## Key facts

- **NCT ID:** NCT04156178
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2019-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156178, "CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04156178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*